2024 Austin Marathon: February 18
Join select AFTD staff and members of the local community at the 2024 Austin Marathon as we bring greater FTD awareness to the surrounding Austin area and raise funds to help people affected by FTD. The AFTD-Team will participate in the Austin Marathon on February 18, as an Official Charity Team. We hope you’ll join…
Read More2024 Austin Marathon
Join select AFTD staff and members of the local community at the 2024 Austin Marathon as we bring greater FTD awareness to the surrounding Austin area and raise funds to help people affected by FTD. The AFTD-Team will participate in the Austin Marathon on February 18, as an Official Charity Team. We hope you’ll join…
Read MoreMeet AFTD’s West Virginia Ambassador
Meet West Virginia AFTD Ambassador Debbie Elkins at the Huntington Mall in Barboursville, W.V., from 11 a.m. – 2 p.m. ET on Saturday, February 17!
Read MoreTreat FTD Fund Grant Recipient Discusses FTD-GRN Gene Therapy in Newspaper Interview
Simon Ducharme, MD, MSc, FRCPC, of McGill University, a recent recipient of a grant through the Treat FTD Fund, discussed an experimental gene therapy for FTD-GRN in a December interview with the Quebec French-language newspaper Le Devoir. Approximately 40% of people diagnosed with FTD have a family history of one or more blood relatives diagnosed…
Read MoreViewpoints of FTD: Addressing Barriers to Diagnosis, FTD Care, and Research Participation Faced by Black/African Americans
In 2011, researchers estimated there to be 50,000-60,000 cases of FTD in the United States. Today, however, researchers believe this figure to be an undercount. One reason for this is a notable lack of representation of diverse populations in FTD research, such as the Black/African American community. Research on the experience of Black/African Americans on…
Read MoreFDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy
The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy designation” to latozinemab, an experimental treatment for FTD caused by a GRN genetic mutation. The drug is being developed by Alector in partnership with biopharmaceutical firm GSK. “With this designation, we look forward to continued productive conversations with the FDA, recognizing the unmet…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)